Agilent (A) announced that its MMR IHC Panel pharmDx has received FDA approval as a companion diagnostic test for colorectal cancer. This test aids in identifying mismatch repair deficient colorectal cancer patients who are eligible for treatment with Bristol Myers Squibb’s (BMY) Opdivo alone or Opdivo in combination with Yervoy. The MMR IHC Panel pharmDx is approved for exclusive use with the Agilent Dako Omnis automated staining solution.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on A: